Executive Board

Madhav Kamat
Madhav Kamat Ph.D R.Ph.

President & Chief Executive Officer

Dr. Kamat has 30+ years of industrial experience in large pharmaceutical companies specializing in the area of sterile injectable products and processes. He worked for seven years at Centocor, Johnson & Johnson, and Somatogen. Dr. Kamat worked at Bristol-Myers Squibb Company for seventeen years – most recently as the Director in Manufacturing Technology of Sterile/Biologics products.

He is a recognized expert in the fields of lyophilization, injectable particulate systems (micro- nano-suspensions and liposomes), microspheres, aseptic technology, and topical/dermaceutical products. Following is a list of some products that Dr. Kamat was involved in development/launch/support:

o Biologicals: Opdivo, Yervoy, Nulojix IV, Orencia SC and IV, Erbitux, Remicade, Repro
o Small molecules: Ixempra, Tequin, Ketorolac, and Acyclovir
o Cytotoxics: Taxol, BicNu, Cytoxan, Carboplatin, Doxorubicin, Mutamycin, Etopophos
o Unique: Triamcinolone suspension, Amphotericin, others
o Ophtlamics: Cyclosprine, Loteprednol

In the last few years, Dr. Kamat has led Kamat Pharmatech to provide extensive CMC development support to >10 innovative small-molecule and biotech companies, as well as large pharmaceutical companies. Some of the formulations developed during this time are already approved and are in the market.

His extensive pharmaceutical background has enabled Kamat Pharmatech to pursue a robust portfolio of unique injectable and topical products.

Dr. Kamat serves as a registered pharmacist in the State of New Jersey. He is also a regular course director for "Lyophilization Technology" in the US, Europe, and the rest of the world.

Jayant Desai Ph.D

Chief Operating Officer

Dr. Desai completed his Ph.D. from Penn State University and later did his post-doctoral studies from University of Kansas and University of Kentucky in drug metabolism and medicinal chemistry. He has over 30 years of pharmaceutical experience. He worked in generic (Par Pharmaceuticals) and research-based pharmaceutical companies (Warner Lambert and Wyeth) in the areas of analytical and product development. Most recently, he worked at Schering Plough / Merck in clinical manufacturing and project management. Dr. Desai's expertise lies in the areas of drug distribution and penetration of opthalmic as well as injectable particulate systems. At Kamat Pharmatech, Dr. Desai is managing the product development portfolio. He also oversees technology transfer to commercial manufacturing and coordinates logistics for launch and distribution.

View Jayant Desai Ph.D.'s profile on LinkedIn

Shridhar Kamat M.BS

Director of Strategic Development

Shridhar Kamat has been involved with Kamat Pharmatech since its inception and has played an integral role in the strategic development and technical advancement of its laboratories. He received a Masters degree in Biomedical Science from Rutgers University and is currently studying medicine at Rutgers New Jersey Medical School. Upon graduation he plans to continue working with Kamat Pharmatech to expand its clinical focus. His association with the university allows him to collaborate with faculty and the medical community. His primary focus at Kamat Pharmatech consists of leveraging his network to expand the company into nascent fields of personalized medicine and targeted immunotherapy. Upon completion of medical licensure exams he plans to oversee clinical trials for 505(b)2 and novel products. 

View Shridhar Kamat's profile on LinkedIn

Scientific Advisory Board

Patrick P. DeLuca, Ph.D.

Dr. Patrick P. DeLuca is a emeritus professor, faculty of Pharmaceutical Sciences, at the College of Pharmacy, University of Kentucky, Lexington, KY. He received his B.S. in 1957 from Temple University, spent 2 years at Smith, Kline and French Labs as an Analytical Chemist, received his M.S. in 1960 and his Ph.D. in 1963 from Temple University.  In 1963, he joined the CIBA Pharmaceutical Company as a Senior Research Pharmacist.  In 1967 he was named the Plant Manager for CIBA‑ Somerville Operations and in 1969 became Director of Development and Control until July 1970 when he joined the University of Kentucky and currently is Professor in the Pharmaceutical Sciences Department.

             Dr. DeLuca's major teaching and research responsibilities and interests are in the area of Pharmaceutical Technology. He has published over 200 research articles on lyophilization, photochemistry, stability testing, complexation, I.V. therapy, microsphere drug delivery, and particulate matter monitoring and has several professional publications on pharmacy education. 

            Dr. DeLuca has received numerous awards during his illustratious career including the Swintosky Distinguished Lecturer at the University of Kentucky College of Pharmacy in 2003.  He was chosen as a Distinguished Alumnus of Temple University as well as his selection for an Honorary Doctorate at the University of Perugia in Italy.

            Dr. DeLuca served as President of the American Pharmaceutical Association's Academy of Pharmaceutical Sciences in 1979, and is a Fellow of the Academy.  He is a founding member and Fellow of the American Association of Pharmaceutical Scientists and a current member of the Executive Council. He has served as a member of the F.D.A‑U.S.P. sponsored National Coordinating Committee to study the problems involved with large volume parenteral solutions.  Dr. DeLuca was Editor-in-Chief of the international journal, Pharmaceutical Development and Technology 1995-1999 and is now the Editor-in-Chief of AAPS online journal PharmSciTech.  He serves on the editorial board of several scientific journals and is a consultant to the F.D.A. and the pharmaceutical industry.

Christopher M. Cimarusti, Ph.D.

Dr. Christopher M. Cimarusti obtained a B.S degree in Chemistry at Providence College as a four-year participant in the NIH-sponsored Honors Science Program. He obtained a Ph.D. in Organic Chemistry from Purdue University and performed Postdoctoral Research at Columbia University with Professor Gilbert Stork.

He spent 37 years at Squibb/Bristol-Myers Squibb and held senior positions in the Squibb Institute for Medical Research, the Squibb Chemical Division, and the Bristol-Myers Squibb Pharmaceutical Research Institute. His last position was Senior Vice President with responsibility for all of the BMS CMC disciplines, Clinical Supply Operations, Project and Portfolio Management. He co-led the Operating Committee that oversaw the early development of the BMS portfolio (30-40 individual project compounds). Dr. Cimarusti was awarded more than 60 patents and has published more than 40 papers in referred journals in the areas of cardiovascular, steroid and β-lactam chemistry. He has contributed chapters to several books including a recent one on the Discovery-Development transition.

Dr. Cimarusti has close to 50 years of experience in the discovery, development and manufacture of small molecules as new medicines as well as Project and Portfolio Management. He currently serves as a consultant to small and big Pharma and biotechnology companies in various roles, providing advice and strategy at the project, portfolio and company level. He serves on several Scientific Advisory Boards and is a Director of Neuland Laboratories, Ltd.

Deodatt (Deo) A. Wadke, Ph.D.

Dr. Wadke began his career in the pharmaceutical industry in 1966 when he joined Merck, Sharp & Dohme (now Merck, Inc.) as a Research Associate and worked in the Exploratory Research Section of the Pharmaceutical Development Department. He moved to Squibb (now Bristol-Myers Squibb - BMS) in 1969 and elected to retire in January, 1994 as Director of Pharmaceuticals R&D, New Brunswick site. As Director, Dr. Wadke was responsible for the physico-chemical characterization of new chemical entities, development of oral solid and parenteral products from conception to plant introduction, manufacture and packaging of phase I-IV clinical supplies and generation of technical data packages for the U.S. and overseas regulatory filings. He is familiar with contemporary cGMP requirements, including those for pharmaceutical manufacturing and testing operations.

Since his retirement from BMS, Dr. Wadke has worked as a consultant to the pharmaceutical industry in the areas of product development and regulatory compliance serving PhRMA, generic and start-up companies in the U.S. and overseas. He is a co-founder and board director of Thubrikar Aortic Valve, Inc. involved in the development of a trans-catheter aortic valve and delivery system. He has published various articles in peer-reviewed journals and has served as an adjunct professor at Long Island University.

He holds a Ph.D. in Med. Chemistry from State University of New York at Buffalo as well as a M.S. in Physical Pharmacy from Ohio State University, and a B.S. in Pharmacy from Banaras Hindu University, where he stood first in the graduating class and was the recipient of Aruna prize.